A multicenter, double-blind, placebo-controlled, phase III vaccine trial is now underway for post-resection melanoma patients with a high risk of recurrence.
Skin Cancer / Melanoma Targets
Because of the high mutation rate in melanoma cells, cancer drugs have been developed to help target these signaling pathways that stimulate such rapid growth. While many of these drugs have proven to be successful, resistance to these same drugs can also occur.
When it comes to cutaneous malignant melanoma (CMM), BRAF V600E is a common mutation found in approximately 50% of cases. Currently, BRAF mutations are detected by using DNA tests, but there may be an alternative assay that's less expensive, requires less tissue, more efficient, and thought to be more sensitive.
The PD-1 inhibitor nivolumab increased progression-free and overall survival compared with chemo in patients with previously untreated metastatic melanoma.
A drug used to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), is also helping to boost the effectiveness of radiation for those melanoma patients with metastasis to the brain.
A mechanism that leads to resistance to certain targeted therapy drugs for melanoma has been discovered by researchers at the Moffitt Cancer Center in Tampa, Fla.
Non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin, may protect against cutaneous squamous cell carcinoma (cSCC), according to the results of a meta-analysis.
Exelixis and their partner Roche are seeking fast-tracked FDA approval for their combination therapy drug for people with BRAF V600 mutation-positive advanced melanoma.
Pembrolizumab (Keytruda) became the leader of the PD-1 and PD-L1 antibody pack by crossing the finish line first, and successfully being granted accelerated FDA approval in September 2014 based on tumor responses and durability of the responses seen in early clinical trials.
As most of you know, at the ends of chromosomes are stretches of DNA called telomeres. Each time a cell divides, it becomes shorter, losing the ability to further replicate. This shortening process is associated with not only aging and a higher risk of death, but with cancer as well.